Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

Sponsor
University of Miami
Study ID
NCT03022565
Phase
EARLY_PHASE1
Status
Withdrawn

Conditions

  • Uveal Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vorinostat — DRUG
    Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.

Study Details

This proof-of-concept study will evaluate the ability of vorinostat to induce the transformation of Class 2 uveal melanoma cells into a cell phenotype that resembles normal melanocytes.

Key Dates

Start date
Jan 31, 2020
Status verified
Feb 2020
Primary completion
Jan 29, 2020
Completion
Jan 29, 2020

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vorinostat
    Vorinostat: * 400 mg orally, once daily for 15 days.

Primary Outcome Measure

Degree of transformation from a class 2 phenotype into a cell phenotype that resembles normal melanocytes. [ Time Frame: From Baseline to 15 Days of Protocol Therapy, Up to 4 Weeks ]

Related Studies